Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel

Drug Review Profile of TNF-inhibitor etanercept-szzs examines how US FDA navigated its way around ‘inaccurate’ pediatric psoriasis labeling for the reference product, Amgen’s Enbrel, to reflect current state of the knowledge on the biosimilar’s labeling, albeit only temporarily.

In approving Sandoz Inc.’s Erelzi (etanercept-szzs), FDA found itself caught between wanting to label the biosimilar as closely as possible to the reference product, Amgen Inc.’s Enbrel, while also recognizing that Enbrel’s pediatric labeling did not accurately reflect the existing data.

Ultimately, FDA used the biosimilar’s labeling to advance the state of the knowledge, even if only temporarily, about etanercept use...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Review Profiles

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>